| Literature DB >> 26336639 |
Michele M Ciulla1, Matteo Astuti2, Stefano Carugo3.
Abstract
Background. The ischemic damage of the sinus node (SN) is a well known cause of cardiac arrhythmias and can be a consequence of any flow abnormality in the sinus node artery (SNA). Accordingly we aimed this retrospective study to: (1) evaluate the suitability of the standard coronary angiography to study the SNA and (2) determine if the percentage of subjects with a positive retrospective history of supra-ventricular arrhythmias (SVA) differs in patients with normal and diseased SNA ascertained at the time of coronary angiography. Methods and Results. Out of the 541 coronary angiograms reviewed the SNA was visible for its entire course in 486 cases (89.8%). It was found to arise from the right side of the coronary circulation in 266 cases (54.7%) slightly more often than from the left, 219 cases (45.1%). One patient had 2 distinct SNA arising from either side of the coronary circulation. For the second objective, we studied the 333 patients with: (a) coronary artery disease (CAD), (b) properly evaluable SNA and (c) complete clinical history available. In 51 (15.3%) a SNA disease was found, 41.2% of them had a positive SVA history, mainly atrial fibrillation (AF), whereas only 7.4% of patients with a positive history of SVA could be found in the non-SNA diseased. This difference was statistically significant (P < 0.001). Conclusions. (1) The evaluation of the SNA is feasible in clinical practice during a standard coronary angiography; (2) this may be relevant since angiographically detectable SNA disease was significantly associated with a positive history of SVA.Entities:
Keywords: Atherosclerosis; Atrial fibrillation; Coronary angiography; Ischemia; Sinus node artery; Supraventricular arrhythmias
Year: 2015 PMID: 26336639 PMCID: PMC4556151 DOI: 10.7717/peerj.1156
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
SNA anatomy.
Summary of the anatomical characteristics of the SNA visualized in this study.
| No | % | |
|---|---|---|
| Total number of coronary angiograms reviewed | 541 | |
| Entirely visibe SNA | 486 | 89.8 |
| Left-sided SNA | 219 | 45.1 |
| Right-sided SNA | 266 | 54.7 |
| Bilateral SNA | 1 | 0.2 |
Figure 1Flow chart showing patient selection according to the exclusion criteria.
∗, patients without medical record were excluded (n = 67); ∗∗, only the older angiography was considered for those patients who repeated the exam; ∗∗∗, this group comprehends the images obtained from the primary coronary catheterizations of patients affected by ACS where the SNA branched downstream the culprit lesion.
Characteristics of the studied patients.
Tables patients groups and characteristics. P < 0.05 is considered statistically significant.
| Characteristics | Total | SNA disease | No SNA disease | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | SVA+ | SVA- | Total | SVA+ | SVA- | P1 | P2 | P3 | P3c | |||
| Patients groups | No | 333 | 51 | 21 | 30 | 282 | 21 | 261 | ||||
| % | 100 | 15.3 | 41.2 | 58.8 | 84.7 | 7.4 | 92.6 | |||||
| Age (yr) | Median | 68 | 73 | 77 | 69.5 | 67 | 74 | 66 | 0.052 | 0.059 | 0.058 | 0.178 |
| IR | 60–78 | 61–80.5 | 70–82 | 57–78 | 59–76 | 70–78 | 58–76 | |||||
| Female sex | No | 88 | 11 | 5 | 6 | 77 | 6 | 71 | 0.744 | 0.892 | 0.393 | 0.251 |
| % | 26.4 | 21.6 | 23.8 | 20.0 | 27.3 | 28.6 | 27.2 | |||||
| ACS (STEMI) | No | 217 (94) | 32 (12) | 13 (3) | 19 (9) | 185 (82) | 10 (3) | 175 (79) | 0.917 | 0.071 | 0.693 | 0.438 |
| % | 65.2 (43.3) | 62.7 (37.5) | 61.9 (23.1) | 63.3 (47.4) | 65.6 (44.3) | 47.6 (30.0) | 67.0 (45.1) | |||||
| Hypertension requiring treatment | No | 237 | 42 | 20 | 22 | 195 | 15 | 180 | 0.640 | 0.814 | 0.055 | 0.732 |
| % | 71.2 | 82.4 | 95.2 | 73.3 | 69.1 | 71.4 | 69.0 | |||||
| Prior AMI | No | 89 | 22 | 10 | 12 | 67 | 3 | 64 | 0.589 | 0.425 |
|
|
| % | 26.7 | 43.1 | 47.6 | 40.0 | 23.8 | 14.3 | 24.5 | |||||
| DM | No | 75 | 11 | 3 | 8 | 64 | 2 | 62 | 0.490 | 0.178 | 0.859 | 0.627 |
| % | 22.5 | 21.6 | 14.3 | 26.7 | 22.7 | 9.5 | 23.8 | |||||
| PAD | No | 89 | 18 | 9 | 9 | 71 | 7 | 64 | 0.344 | 0.371 | 0.133 | 0.604 |
| % | 26.7 | 35.3 | 42.9 | 30.0 | 25.2 | 33.3 | 24.5 | |||||
|
| 0.189 | 0.221 | 0.693 | 0.097 | ||||||||
| Current | No | 89 | 14 | 3 | 11 | 75 | 3 | 72 | ||||
| % | 26.7 | 27.5 | 14.3 | 36.7 | 26.6 | 14.3 | 27.6 | |||||
| Former | No | 84 | 15 | 8 | 7 | 69 | 8 | 61 | ||||
| % | 25.2 | 29.4 | 38.1 | 23.3 | 24.5 | 38.1 | 23.4 | |||||
| Never | No | 160 | 22 | 10 | 12 | 138 | 10 | 128 | ||||
| % | 48.1 | 43.1 | 47.6 | 40.0 | 48.9 | 47.6 | 49.0 | |||||
| Left ventricle ejection fraction <55% | No | 128 | 26 | 12 | 14 | 102 | 13 | 89 | 0.461 |
|
| 0.756 |
| % | 38.4 | 51.0 | 57.1 | 46.7 | 36.2 | 61.9 | 34.1 | |||||
|
|
|
| 0.431 | 0 | ||||||||
| Na | No | 145 | 18 | 7 | 11 | 127 | 7 | 120 | ||||
| % | 43.4 | 35.3 | 33.3 | 36.7 | 45.0 | 33.3 | 46.0 | |||||
| No | No | 110 | 19 | 4 | 15 | 91 | 4 | 87 | ||||
| % | 33.0 | 37.3 | 19.1 | 50.0 | 32.3 | 19.0 | 33.3 | |||||
| Yes (mild) | No | 78 (45) | 14 (11) | 10 (7) | 4 (4) | 64 (34) | 10 (2) | 54 (32) | ||||
| % | 23.4 (57.7) | 27.4 (78.6) | 47.6 (70) | 13.3 (100) | 22.7 (53.1) | 47.7 (20) | 20.7 (59.3) | |||||
| Cholesterol level: total (mg/dl) | Median | 172 | 166 | 172 | 153 | 172 | 149 | 173 | 0.393 |
| 0.302 | 0.103 |
| IR | 143.5–200.5 | 143–190 | 155–191 | 136–186 | 144–204.5 | 136–180 | 145–208 | |||||
| Cholesterol level: HDL (mg/dl) | Median | 43 | 42 | 42 | 39.5 | 43 | 43.5 | 43 | 0.153 | 0.986 | 0.337 | 0.123 |
| IR | 35.5–52 | 35.5–49.5 | 38–50 | 32–48 | 36–52 | 37–53 | 35–52 | |||||
| TGL (mg/dl) | Median | 115 | 105 | 110 | 104 | 117 | 95 | 119 | 0.916 |
| 0.379 | 0.073 |
| IR | 82–153.5 | 83–149 | 95–145 | 79–153 | 82–155 | 63–131 | 88–159 | |||||
| Hyperthyroidism | No | 6 | 2 | 0 | 2 | 4 | 1 | 3 | 0.506 | 0.267 | 0.230 | 0.431 |
| % | 1.8 | 3.9 | 0.0 | 6.7 | 1.4 | 4.8 | 1.1 | |||||
|
| 0.092 |
| 0.108 | 0.711 | ||||||||
| CKD stage 0–1, ≥90 | No | 78 | 9 | 1 | 8 | 69 | 2 | 67 | ||||
| % | 23.4 | 17.6 | 4.8 | 26.7 | 24.5 | 9.5 | 25.7 | |||||
| CKD stage 2, ≥60 to 89 | No | 163 | 24 | 9 | 15 | 139 | 12 | 127 | ||||
| % | 48.9 | 47.1 | 42.8 | 50.0 | 49.3 | 57.1 | 48.6 | |||||
| CKD stage 3, ≥30 to 59 | No | 79 | 13 | 8 | 5 | 66 | 6 | 60 | ||||
| % | 23.7 | 25.5 | 38.1 | 16.7 | 23.4 | 28.6 | 23.0 | |||||
| CKD stage 4, ≥15 to 29 | No | 12 | 5 | 3 | 2 | 7 | 0 | 7 | ||||
| % | 3.6 | 9.8 | 14.3 | 6.6 | 2.5 | 0.0 | 2.7 | |||||
| CKD stage 5, <15 | No | 1 | 0 | 0 | 0 | 1 | 1 | 0 | ||||
| % | 0.3 | 0.0 | 0.0 | 0.0 | 0.3 | 4.8 | 0.0 | |||||
| ACE inhibitor/ARB | No | 163 | 30 | 10 | 20 | 133 | 13 | 120 | 0.174 | 0.160 | 0.125 | 0.347 |
| % | 48.9 | 58.8 | 47.6 | 66.7 | 47.2 | 61.9 | 46.0 | |||||
| Amiodarone | No | 7 | 3 | 3 | 0 | 4 | 2 | 2 | 0.064 |
| 0.076 | 0.534 |
| % | 2.1 | 5.9 | 14.3 | 0.0 | 1.4 | 9.5 | 0.8 | |||||
| Beta-blocker | No | 112 | 24 | 11 | 13 | 88 | 9 | 79 | 0.524 | 0.231 |
| 0.524 |
| % | 33.6 | 47.1 | 52.4 | 43.3 | 31.2 | 42.9 | 30.3 | |||||
| Digoxin | No | 3 | 1 | 1 | 0 | 2 | 2 | 0 | 0.412 |
| 0.394 | 0.667 |
| % | 0.9 | 2.0 | 4.8 | 0.0 | 0.7 | 9.5 | 0.0 | |||||
| Calcium blocker | No | 59 | 10 | 3 | 7 | 49 | 7 | 42 | 0.495 | 0.067 | 0.701 | 0.986 |
| % | 17.7 | 19.6 | 14.3 | 23.3 | 17.4 | 33.3 | 16.1 | |||||
| ASA | No | 156 | 26 | 10 | 16 | 130 | 9 | 121 | 0.688 | 0.757 | 0.520 | 0.889 |
| % | 46.8 | 51.0 | 47.6 | 53.3 | 46.1 | 42.9 | 46.4 | |||||
| Thienopyridine | No | 47 | 12 | 4 | 8 | 35 | 1 | 34 | 0,739 | 0,489 |
| 0.264 |
| % | 14.1 | 23.5 | 19.0 | 26.7 | 12.4 | 4.8 | 13.0 | |||||
| IC antiarrhythmic drugs | No | 7 | 3 | 3 | 0 | 4 | 4 | 0 | 0.064 |
| 0.076 | 0.665 |
| % | 2.1 | 5.9 | 14.3 | 0.0 | 1.4 | 19.0 | 0.0 | |||||
| Statin | No | 110 | 19 | 8 | 11 | 91 | 7 | 84 | 0.917 | 0.914 | 0.486 | 0.847 |
| % | 33.0 | 37.3 | 38.1 | 36.7 | 32.3 | 33.3 | 32.2 | |||||
| Sotalol | No | 2 | 1 | 1 | 0 | 1 | 0 | 1 | 0.421 | 1 | 0.283 | 0.345 |
| % | 0.6 | 2.0 | 4.8 | 0.0 | 0,4 | 0.0 | 0.4 | |||||
Notes.
subjects with a positive history of SVA
subjects without a positive history of SVA
comparison between subjects affected by SNA disease with and without SVA
comparison between subjects not affected by SNA disease with and without SVA
comparison between subjects with and without SNA disease
correction for multiple testing
not assessable
Figure 2Representative angiographic images of the SNA (arrows) demonstrating the general feasibility of its visualization.
(A) a normal SNA; (B) SNA with a focal stenosis (arrowhead); (C) diffuse atherosclerotic disease involving also the SNA; (D) stenosis of the main left coronary artery upstream the SNA (arrowhead).
Classification of SVA.
Distribution of the different kinds of SVA observed according to the presence or not of SNA disease.
| Supraventricular arrhythmias | All patients | SNA disease | No SNA disease | |
|---|---|---|---|---|
| Total | No. (%) | 42 (100) | 21 (50) | 21 (50) |
| AF | 35 (83.3) | 17 (81) | 18 (85.7) | |
| Paroxysmal AF | 9 (21.4) | 5 (23.8) | 4 (19) | |
| Persistent AF | 12 (28.6) | 7 (33.3) | 5 (23.8) | |
| Permanent AF | 14 (33.8) | 5 (23.8) | 9 (42.9) | |
| Sick sinus syndrome | 3 (7.1) | 3 (14.3) | 0 (0) | |
| SV PACs requiring antiarrhythmic therapy | 2 (4.8) | 0 (0) | 2 (9.5) | |
| Paroxysmal supraventricular tachycardia | 2 (4.8) | 1 (4.8) | 1 (4.8) | |
Figure 3Pie chart showing the prevalence of SVA history in subjects with and without SNA disease.